INTRODUCTION AND OBJECTIVES: Radical cystectomy (RC) with urinary diversion has a high rate of perioperative surgical site infection leading to significant morbidity. In the evaluation of bladder cancer, patients undergo frequent urinary instrumentation and exposure to oral prophylactic antibiotics which may alter the microbiome. Using a national sample database, we aimed to determine exposure rates to outpatient antibiotics prior to radical cystectomy and their correlation with post-operative infections.
METHODS: 2248 patients in the SEER-Medicare database underwent radical cystectomy between 2008 and 2014 and had requisite prescription claims information. An outpatient prescription for any antibiotic within 30 days prior to cystectomy was considered exposure. Postoperative infection claims, readmissions, and deaths were tabulated within 30 days of operation.
RESULTS: Within the cohort, 1,149 (51.1%) patients were identified to have been prescribed outpatient antibiotics before cystectomy. 545 (31.9%) of the prescriptions were for a fluoroquinolone. Only 94 (8.2%) of these patients were diagnosed with a preoperative UTI. Patients receiving outpatient antibiotics were more likely to be female (p<.001) and have a higher Elixhauser comorbidity index (p<.0001). Those who received antibiotics before RC were more likely to be diagnosed postoperatively with any infection (56% vs 51% p<0.01), pneumonia (13% vs 9%, p<0.01), and UTI (36% vs 31% p<0.01). There was no difference in Clostridium difficile infection, sepsis or mortality within 30 days. Multivariate logistic regression controlling for other identified risk factors (including preoperative UTI and comorbidity index) confirmed that receiving a preoperative outpatient antibiotic is in an independent risk factor for postoperative infection (HR 1.19, p [ 0.05) and readmission (HR 1.24, p[0.03) .
CONCLUSIONS: Outpatient antibiotic use before RC for bladder cancer is associated with increased risk of postoperative infection and readmission within 30 days. Judicious antibiotic use in the evaluation of bladder cancer should be considered to decrease morbidity associated with RC.
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COST AND UTI RATE FOLLOWING OFFICE CYSTOSCOPY BEFORE AND AFTER IMPLEMENTING NEW STANDARDIZED HANDLING AND STORAGE PRACTICES Vincent Roth*, Pedro Espino-Grosso, Carl Henriksen, Benjamin Canales, Gainesville, FL INTRODUCTION AND OBJECTIVES: In 2011, our facility transitioned from sterile to high-level disinfection (HLD) reprocessing of flexible cystoscopes following an AUA white paper that endorsed both as acceptable practices. Our objective was to examine the effect of this change by evaluating cost and symptomatic UTI rates before and after implementation.
METHODS: We retrospectively reviewed 30-day outcomes following 1,888 simple cystoscopy encounters that occurred from 2007 -2010 n [ 905) and 2012-2015 (HLD conditions; n [ 983) at the Malcom Randall VA. We excluded patients who had recent urologic instrumentation, active or recent UTI, performed intermittent catheterization, or had complicated cystoscopy (dilation, biopsy, etc). Procedural indications, patient demographics and comorbidities, prophylactic antibiotic use, postprocedural complications, and reprocessing costs were collected and compared between groups. Statistical significance between groups was assessed using Fisher's exact test.
RESULTS: Both cohorts were predominantly Caucasian (82.5%) with mean age 68AE10.5 years. Most common indications were cancer surveillance (50%) and hematuria (34%). Common comorbidities included a history of cancer (62%), type 2 diabetes mellitus (36%), and tobacco use (24.5%). Across both cohorts, overall rate of urological complications was 1.43%. Reported UTI events occurred in 9/905 (0.99%) of sterile and 5/983 (0.51%) HLD group (p [ 0.29). Unplanned clinic/ED visits occurred in 6/905 (0.66%) of sterile and 7/983 (0.71%) HLD groups. Prophylactic antibiotics, most commonly fluoroquinolones (91%), were prescribed in over 99% of both cohorts. HLD was significantly cheaper ($82.32) per procedure than sterile conditions with the majority of cost disparity stemming from reprocessing. Total annual savings by switching to HLD was w$101,000 for our facility.
CONCLUSIONS: In our older, highly morbid veteran population receiving centralized care and prophylactic antibiotics, we found no difference in UTI rate between sterile and HLD techniques. HLD comes with a sizable cost savings, easier scope access/storage, and easier procedure preparation. The UTI rate of 0.79% is the lowest postprocedural UTI rate ever reported in the literature, perhaps due to pervasive prophylactic antibiotic use.
